Fast Money

Monday - Friday, 5:00 - 6:00 PM ET
Fast Money

No. 3 - Alzheimer's Epidemic?

New data reveals 1 in 85 people worldwide will suffer from Alzheimer’s disease by 2050. At a conference in Washington DC drug companies ranging from Glaxo (GSK) to Eli Lilly (LLY) are presenting data on their new drugs to combat this devastating disease. Early word suggests a new drug from Medivation (MDVN) is showing promise in trials.

CNBC Pharmaceutical Reporter Mike Huckman joins the guys for this conversation.

Mike says a trio of biotech stocks moved on the data coming out of the conference. MDVN is testing an anti-histamine from Russia on Alzheimer’s patients and early results suggest the drug might stabilize and perhaps improve the mental acuity of patients.

Top Three #3

He adds Neurochem (NRMX) and Myriad Genetics (MYGN) also moved on their Alzheimer’s treatments.

Mike also says Wyeth (WYE) is leading the pack with almost a dozen Alzheimer’s drug in clinical trials right now. Also, he says Eli Lily (LLY) announced some positive test results.

Pete Najarian says he loves Myriad Genetics for its pipeline.

On a different note, Mike explains that on Wednesday an FDA advisory committee will meet to discuss a weight loss drug from Sanofi-Aventis (SNY) which works on the same receptors in the brain stimulated by marijuana.

Jeff Macke expects companies to pour billions into weight loss and Alzheimer’s research because it’s a boomer problem - and one that’s not going away.

Got something to say? Send us an e-mail at and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to .

Trader disclosure: On June 11 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders:
Najarian Owns (MNKD), (AAPL), (VSE), (ELN), (MYGN), (TXN) Bolling Owns Sugar, (BP); Bolling Is Short S&P And Nasaq Futures; Bolling Has Closed Out Of His Coffee Trade
GE Is The Parent Company Of CNBC; CNBC Is A Service Of NBC Universal And Dow Jones